Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Insight into Rapid Evolution of AMR in Patients Calls for Shift in Diagnostic Testing Approaches

By LabMedica International staff writers
Posted on 01 Aug 2023

A groundbreaking research study has offered novel insights into the development of antimicrobial resistance (AMR) in patients suffering from bacterial infections. More...

This could lead to more effective preventative strategies against AMR infections in susceptible individuals. Contrary to the conventional belief that infection typically occurs due to a single strain of bacteria that develops resistance through new genetic mutations, the study suggests that patients often get co-infected by multiple clones of pathogens. In these cases, resistance arises from the selection of already resistant clones rather than new mutations.

In the study led by the University of Oxford (Oxford, UK), the researchers utilized an innovative technique to examine genetic alterations and antibiotic resistance in Pseudomonas aeruginosa, a common hospital-acquired bacterium, particularly among immunocompromised and severely ill individuals. Samples were taken from 35 patients in intensive care units across 12 European hospitals. Approximately two-thirds of the patients were found to be infected by a single strain of Pseudomonas, in some of which AMR developed due to new mutations, as traditionally believed. However, in a surprising revelation, one-third of patients were infected by multiple strains of the bacteria. It was observed that patients with mixed-strain infections exhibited a roughly 20% higher increase in resistance when exposed to antibiotic treatment compared to those with single-strain infections. The spike in resistance was primarily attributed to the selection of pre-existing resistant strains that already existed prior to antibiotic therapy.

Interestingly, the study also found that such resistance could decline rapidly under certain conditions. When samples from single-strain and mixed-strain infections were cultured without antibiotics, the growth rate of AMR strains was slower compared to non-AMR strains. This supports the idea that AMR genes carry fitness trade-offs and are negatively selected when antibiotics are absent. This effect was more pronounced in mixed strain populations, suggesting that a diverse bacterial environment could contribute to resistance loss in the absence of antibiotics.

The findings suggest that strategies focusing on controlling bacterial transmission among patients, such as improved sanitation and infection control measures, might be more effective against AMR compared to efforts to prevent new resistance mutations. This is particularly important in settings with a high infection rate, like immunocompromised individuals. Additionally, the study calls for a shift in clinical testing, emphasizing the importance of considering pathogen strain diversity instead of assuming a singular strain during infection assessments. This approach could aid in making more accurate predictions about antibiotic treatment effectiveness and improve patient outcomes, similar to the use of diversity measurements in cancer cell populations to predict chemotherapy success.

"The diagnostic methods employed for assessing antibiotic resistance in patient samples have undergone slow evolution over time, and our findings highlight the significance of developing new diagnostic approaches that facilitate the assessment of pathogen population diversity in patient samples," said Professor Craig Maclean, the lead researcher from the University of Oxford's Department of Biology.

Related Links:
University of Oxford 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.